Given the importance of β‐TrCP in ESCC development and the potential to develop novel therapies through regulating β‐TrCP stability, it is in urgent need to investigate the process of β‐TrCP deubiquitination. This evidence concerns the gene BTRC and esophageal squamous cell carcinoma.